| Exec date | Filing date | Company | Role | Signal | Confidence | Shares | % of shares | Under plan? | Amount (USD) |
|---|---|---|---|---|---|---|---|---|---|
| Sep 7, 2025 | Sep 9, 2025 | UroGen Pharma Ltd. | General Counsel | Sell | 46.3 | -1,520 | -3.39% | ✗ | $29K |
| Jul 28, 2025 | Jul 30, 2025 | UroGen Pharma Ltd. | General Counsel | Sell | 42.5 | -7,522 | -15.35% | ✗ | $144K |
| Jan 31, 2025 | Feb 4, 2025 | UroGen Pharma Ltd. | General Counsel | Sell | 42.5 | -7,379 | -7.68% | ✗ | $82.2K |
| Sep 9, 2024 | Sep 12, 2024 | UroGen Pharma Ltd. | General Counsel | Sell | 46.3 | -1,521 | -5.69% | ✗ | $19.9K |
| Feb 1, 2024 | Feb 5, 2024 | UroGen Pharma Ltd. | General Counsel | Sell | 22.5 | -4,993 | -7.42% | ✗ | $78.8K |
| Jan 31, 2024 | Feb 2, 2024 | UroGen Pharma Ltd. | General Counsel | Sell | 42.5 | -4,993 | -7.42% | ✗ | $78.6K |
| Aug 31, 2023 | Sep 5, 2023 | UroGen Pharma Ltd. | General Counsel | Sell | 42.5 | -3,800 | -17.11% | ✗ | $68.4K |
| Jan 31, 2023 | Feb 2, 2023 | UroGen Pharma Ltd. | General Counsel | Sell | 46.3 | -1,636 | -5.82% | ✗ | $16.6K |
| Aug 31, 2022 | Sep 2, 2022 | UroGen Pharma Ltd. | General Counsel | Sell | 46.3 | -3,606 | -22.85% | ✗ | $26K |
| Jan 31, 2022 | Feb 2, 2022 | UroGen Pharma Ltd. | General Counsel | Sell | 47.5 | -414 | -5.27% | ✗ | $3.1K |
| Nov 30, 2021 | Dec 2, 2021 | UroGen Pharma Ltd. | General Counsel | Sell | 46.3 | -3,803 | -35.11% | ✗ | $45.8K |
| May 17, 2021 | May 18, 2021 | UroGen Pharma Ltd. | General Counsel | Buy | 91.3 | +2,500 | 100.00% | ✗ | $39.3K |